Search Results

Innocoll Holdings Ltd., a global biotech pharmaceutical company and portfolio business of Gurnet Point Capital, announced the appointment of Kimball Hall, a seasoned commercial operations executive, as President and Chief Executive Officer.

Innocoll, Inc. Limited, a commercial-stage biotechnology company and portfolio business of Gurnet Point Capital, and DURECT Corporation (Nasdaq: DRRX) today announced the recent commercial launch of POSIMIR® (bupivacaine solution) in the United States.

Innocoll Holdings Limited, a specialty pharmaceutical company wholly owned by Gurnet Point Capital, a private investment firm focused on health care, announced that Louis Pascarella has been named the company’s Chief Executive Officer and a member of Innocoll’s Board of Directors.

Innocoll Holdings Limited, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, announced today that Anthony Galdi has been named the Chief Commercial Officer of the Innocoll Group of Companies, effective mid-February. Galdi succeeds Jim Helm, who is retiring and has agreed to assist with the leadership transition. This press release features multimedia. View the full release here: https

Innocoll Pharmaceuticals Limited announced today positive topline results from Study INN-CB-024, a Phase 3 randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a 300mg dose of XARACOLL, an innovative collagen drug-device implant, in patients undergoing abdominoplasty.

- DURECT to receive near-term upfront cash payments totaling $6 million, potential additional milestone payments of up to $130 million and tiered low to mid double-digit royalties based on U.S. sales and Innocoll granted exclusive development and commercialization rights to POSIMIR in the United States.

Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual Wellness Key Highlights: • Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive • Proposed purchase price of approximately $15 million, payable in cash and KALA stock; the cash portion is expected to be funded from existing balance sheet resources • Founded in 2023; LegitScript-certified, NABP-accredited platform serving clients in all 50 states; more than 90,000 clients served since inception • 45-day due diligence period expected to conclude in November 2026; definitive agreements and closing targeted for late 2026 or early 2027